Aerie Pharmaceuticals, a Duke University spinout developing treatments for glaucoma, has signed a research collaboration and license agreement with pharmaceutical company GrayBug, according to Triangle Business Journal.
The research collaboration is set to last for one year. Aerie also gains the exclusive option to license GrayBug’s drug delivery platform to develop and commercialise its drug candidates.
The partnership will have the two companies work together to bring Aerie’s drug candidates to GrayBug’s drug delivery platform, initially focusing on evaluating whether the platform is able to release Aerie’s drug candidates into the body over several months.
GrayBug is, similarly to Aerie, also working on treatments for ocular disorders including glaucoma as well as age-related macular degeneration. Both diseases eventually cause blindness.
